1. Home
  2. CBUS vs ACET Comparison

CBUS vs ACET Comparison

Compare CBUS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cibus Inc.

CBUS

Cibus Inc.

HOLD

Current Price

$3.35

Market Cap

197.5M

Sector

Industrials

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$7.56

Market Cap

69.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBUS
ACET
Founded
2010
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
197.5M
69.6M
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
CBUS
ACET
Price
$3.35
$7.56
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$20.00
$65.33
AVG Volume (30 Days)
539.1K
175.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
58.27
59.82
EPS
N/A
N/A
Revenue
$4,262,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$99.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
134.56
N/A
52 Week Low
$1.09
$0.45
52 Week High
$3.80
$9.05

Technical Indicators

Market Signals
Indicator
CBUS
ACET
Relative Strength Index (RSI) 62.37 56.32
Support Level $1.34 $0.64
Resistance Level N/A $8.46
Average True Range (ATR) 0.37 0.50
MACD 0.04 -0.05
Stochastic Oscillator 76.69 94.92

Price Performance

Historical Comparison
CBUS
ACET

About CBUS Cibus Inc.

Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: